Information released at the 20th World Diabetes Conference,2007 to 2025 Asian diabetic patients will increase 60%,China has become the world's second largest diabetes population。 
Sanofi-Anwte Vice President Wei Ping said in an interview with our reporter,The company will provide 20 million yuan of funds My stake betting appto My stake betting appsupport the research project of the Diabetes Branch of the Chinese Medical Association。Before that,American Pharmaceutical Giant Lilly Company has just brought its latest products to China,Add the participation of multinational pharmaceutical companies such as GlaxoSmiths and some domestic pharmaceutical companies,China's Diabetes Drug Market will face a new round of competition。
 Sanofi Faqi China Market
According to the person in charge of the Diabetes Branch of the Chinese Medical Association,Sanofi supports the "China Type II Diabetes Research Project" this time,That is the adult disease type diabetes,Most of them occur after 35 to 40 years old,More than 90%of patients with diabetes。
Professor Ji Linong, chairman of the Chinese Medical Association Diabetes Branch, emphasized,The prevalence of Chinese diabetes gradually increases,At present, it has become the world's second largest diabetes country after India。The direct medical cost of the country's type II diabetes and its complications is close to 20 billion yuan。Diabetes seriously threatened public health,As a result of a sharp increase in medical expenses,Causes heavy My stake betting appStake Sports Bettingeconomic burdens to the family and society of patients。
Data shows that the direct medical cost of patients with type II diabetes in the Mainland and its complications is 18.75 billion yuan,accounting for 3.94%of the total medical and health expenses of the country,and this data is still rising。
The reporter learned,To further expand its market share in China,Sanofi-Antante announced in April 2009 that it would increase 600 million yuan in investment to the Chinese market,Expansion of an insulin factory located in the Beijing Economic and Technological Development Zone,When the construction comes (glycry insulin) pre -filled SOLOST A R Pre -irrigation production line,This production is expected to be put into production in China,After expansion, the factory capacity will reach 50 million packaging units。
Type II diabetes market competition is fierce
A few days ago,The most exposed exposure in the field of diabetes should belong to the drug of Grandulsc (GSK) for the treatment of diabetes.,This drug is also used for treatment for patients with type II diabetes。In 2007,Wenya has been questioned by security,This time I was pushed to the forefront of the wind。But GlaxoSmith Ki stake betting appstake online sports bettingShi recently issued a statement,The information on which the report was used was still before 2007。This statement has also been affirmed by Professor Ji Linong。
and another giant in the field of diabetes,August 2009,Lilly announced that its type II diabetes new products were officially landed on the Chinese market,This is the first approved product in the world in the past 10 years,Creating a new therapy in addition to oral hypoglycemic drugs and injection insulin。
Sanofi-Antante Vice President Wei Ping said,"2025 global diabetes patients will reach 380 million people,It is increasingly becoming a severe social problem,Coping this problem is not the solution that one or two companies can solve,I hope that more pharmaceutical companies can participate in this competition。”
December 2008,After the CEO of Sanofi Global CEO,China chose China。"Patients in any place in the world are important,But from a market perspective,China is the most important market。"Webach said。